RxDoctor Payments DataLook up a doctor →

Ramin Ansari

Neurology · Frisco, TXNPI 1801048285

Payments from drug & device makers

$838,072in general payments, 2019–2025

Across 1,384 payments — averaging $605.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$764K
  • Amgen$34K
  • Lilly USA, LLC$7K
  • AbbVie$5K
  • Livanova USA, Inc.$2K
  • UCB, Inc.$2K
  • plus $23K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis79$763,951
Amgen(2 entities)44$34,428
Lilly USA, LLC35$6,552
AbbVie(2 entities)243$4,668
Livanova USA, Inc.13$2,266
UCB, Inc.74$2,055
Biogen83$1,869
Teva Pharmaceuticals USA, Inc.62$1,688
EMD Serono, Inc.28$1,415
SK Life Science, Inc.34$1,173
Pfizer60$1,042
AstraZeneca(2 entities)33$976
Biohaven Pharmaceuticals, Inc.21$905
Neurocrine Biosciences, Inc.24$811
Lundbeck LLC47$810
Eisai Inc.16$732
Argenx US, Inc.13$702
Acadia Pharmaceuticals Inc32$682
Sanofi16$645
Genentech USA, Inc.26$584
Jazz Pharmaceuticals Inc.16$529
Kyowa Kirin, Inc.16$509
Bristol Myers Squibb27$507
Grifols USA, LLC15$506
Ipsen Biopharmaceuticals, Inc14$496
Biohaven Pharmaceutical Holding Company Ltd.21$450
TG Therapeutics, Inc.8$392
Sumitomo Pharma America, Inc.14$358
Tanabe Pharma America, Inc.21$345
Johnson & Johnson(2 entities)7$337
Merz Pharmaceuticals, LLC10$297
Upsher-smith Laboratories LLC15$280
CSL Behring12$254
Acorda Therapeutics, Inc8$246
E.r. Squibb & Sons, L.L.C.4$246
Avanir Pharmaceuticals, Inc.17$222
Mallinckrodt Enterprises LLC6$220
Springworks Therapeutics, Inc.6$218
Sunovion Pharmaceuticals Inc.18$216
Avion Pharmaceuticals12$215
Otsuka America Pharmaceutical, Inc.5$208
Octapharma USA, Inc.8$192
Vanda Pharmaceuticals Inc.6$169
MDD US Operations, LLC7$161
Catalyst Pharmaceuticals, Inc.8$153
Amneal Pharmaceuticals LLC4$151
Neurelis, Inc.7$144
Takeda Pharmaceuticals U.S.A., Inc.6$142
GE HealthCare5$127
Adamas Pharmaceuticals, Inc.5$108
Si-bone, Inc.1$105
Axsome Therapeutics, Inc.4$98
Corium, LLC3$96
Tonix Medicines, Inc.4$96
ANI Pharmaceuticals, Inc.4$96
Medtronic3$95
Aprecia Pharmaceuticals, LLC5$95
Globus Medical3$88
Akcea Therapeutics, Inc.1$82
Azurity Pharmaceuticals, Inc.5$81

How this compares

$838,072 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$1,707,436
Medicare patients
953
Services billed
38,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Frisco

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →